keyword
MENU ▼
Read by QxMD icon Read
search

Tamoxifen aromatase

keyword
https://www.readbyqxmd.com/read/29755596/phytochemicals-current-strategies-for-treating-breast-cancer
#1
REVIEW
Bridg'ette B Israel, Syreeta L Tilghman, Kitani Parker-Lemieux, Florastina Payton-Stewart
Females with early-stage metastatic, estrogen-dependent breast cancer are generally treated with surgery, radiation and chemotherapy, or with more targeted approaches such as aromatase inhibitors (anastrozole or letrozole) or anti-estrogens (tamoxifen). Despite widespread successful usage of these agents for the treatment of breast cancer, resistance, tumor relapse and metastasis remain the principal causes of mortality for patients with breast cancer. While numerous groups have made major contributions toward an improved understanding of resistance mechanisms, the currently insufficient grasp of the most critical pathways involved in resistance is evident in the inability to adequately treat and drastically improve patient outcomes in females with hormone-refractory breast cancer, including triple negative breast cancer...
May 2018: Oncology Letters
https://www.readbyqxmd.com/read/29754304/impact-of-high-deductible-insurance-on-adjuvant-hormonal-therapy-use-in-breast-cancer
#2
Christine Y Lu, Fang Zhang, Anita K Wagner, Larissa Nekhlyudov, Craig C Earle, Matthew Callahan, Robert LeCates, Xin Xu, Dennis Ross-Degnan, J Frank Wharam
OBJECTIVE: High-deductible health plans (HDHPs) have become the predominant commercial health insurance arrangement in the US. HDHPs require substantial out-of-pocket (OOP) costs for most services but often exempt medications from high cost sharing. We examined effects of HDHPs on OOP costs and utilization of adjuvant hormonal therapy (AHT), which are fundamental care for patients with breast cancer. METHODS: This controlled quasi-experimental study used claims data (2003-2012) from a large national health insurer...
May 12, 2018: Breast Cancer Research and Treatment
https://www.readbyqxmd.com/read/29752333/the-endocrinology-of-male-breast-cancer
#3
REVIEW
Ian S Fentiman
Male breast cancer (MBC) is a rare disease but, as a result of epidemiological collaborations, there is now greater clarity concerning endocrine risk factors. The significant rise in global age-standardised mean BMI in men is likely to lead to increases in incidence of maturity-onset diabetes and MBC. The metabolic changes accompanying obesity decrease androgens and sex hormone-binding globulin (SHBG), thereby increasing available oestrogens. The higher rates of MBC in North and Equatorial Africa are largely due to liver damage from endemic bilharziasis and hepatitis B causing elevated oestradiol (E2 ) levels from hepatic conversion of androgen...
June 2018: Endocrine-related Cancer
https://www.readbyqxmd.com/read/29741296/assessment-and-management-of-bone-health-in-women-with-oestrogen-receptor-positive-breast-cancer-receiving-endocrine-therapy-position-statement-of-the-endocrine-society-of-australia-the-australian-and-new-zealand-bone-mineral-society-the-australasian-menopause
#4
Mathis Grossmann, Sabashini Ramchand, Frances Milat, Amanda Vincent, Elgene Lim, Mark A Kotowicz, Jill Hicks, Helena Teede
OBJECTIVE: To formulate clinical consensus recommendations on bone health assessment and management of women with oestrogen receptor-positive early breast cancer receiving endocrine therapy. METHODS: Representatives appointed by relevant Australian Medical Societies used a systematic approach for adaptation of guidelines (ADAPTE) to derive an evidence-informed position statement addressing five key questions. RESULTS: Women receiving adjuvant aromatase inhibitors and the subset of premenopausal woman on tamoxifen have accelerated bone loss and increased fracture risk...
May 9, 2018: Clinical Endocrinology
https://www.readbyqxmd.com/read/29739819/endoxifen-4-hydroxytamoxifen-and-an-estrogenic-derivative-modulate-estrogen-receptor-complex-mediated-apoptosis-in-breast-cancer
#5
Philipp Y Maximov, Balkees Abderrahman, Sean W Fanning, Surojeet Sengupta, Ping Fan, Ramona F Curpan, Daniela Maria Quintana Rincon, Jeffery A Greenland, Shyamala S Rajan, Geoffrey L Greene, V Craig Jordan
Estrogen therapy was used to treat advanced breast cancer in postmenopausal women for decades until the introduction of tamoxifen. Resistance to long-term estrogen deprivation (LTED) with tamoxifen and aromatase inhibitors used as a treatment for breast cancer inevitably occurs, but unexpectedly low dose estrogen can cause regression of breast cancer and increase disease free survival in some patients. This therapeutic effect is attributed to estrogen-induced apoptosis in LTED breast cancer. Here we describe modulation of the estrogen receptor liganded with antiestrogens (endoxifen, 4-hydroxytamoxifen) and an estrogenic triphenylethylene (TPE) EthoxyTPE (EtOXTPE) on estrogen-induced apoptosis in LTED breast cancer cells...
May 8, 2018: Molecular Pharmacology
https://www.readbyqxmd.com/read/29721482/practical-consensus-recommendations-on-duration-of-adjuvant-hormonal-therapy-in-breast-cancer
#6
S Gupta, M Singh, Amish Vora, G Babu, M Walia, V Nautial, R Saha, B K Smruti, J B Sharma, R Koul, Purvish M Parikh, S Aggarwal
Optimization of adjuvant systemic therapy in women with early-stage hormone receptor-positive breast cancer includes the consideration of chemotherapy and duration of hormone therapy. Adjuvant hormonal therapy significantly improves long-term survival of breast cancer patients with hormone receptor-positive disease. Despite the proven clinical efficacy of tamoxifen and aromatase inhibitors, many breast cancer survivors either fail to take the correct dosage at the prescribed frequency (adherence) or discontinue therapy (persistence)...
April 2018: South Asian Journal of Cancer
https://www.readbyqxmd.com/read/29720397/increased-long-qt-and-torsade-de-pointes-reporting-on-tamoxifen-compared-with-aromatase-inhibitors
#7
Virginie Grouthier, Benedicte Lebrun-Vignes, Andrew M Glazer, Philippe Touraine, Christian Funck-Brentano, Antoine Pariente, Carine Courtillot, Anne Bachelot, Dan M Roden, Javid J Moslehi, Joe-Elie Salem
OBJECTIVE: A prolonged QTc (LQT) is a surrogate for the risk of torsade de pointes (TdP). QTc interval duration is influenced by sex hormones: oestradiol prolongs and testosterone shortens QTc. Drugs used in the treatment of breast cancer have divergent effects on hormonal status. METHODS: We performed a disproportionality analysis using the European database of suspected adverse drug reaction (ADR) reports to evaluate the reporting OR (ROR χ2 ) of LQT, TdP and ventricular arrhythmias associated with selective oestrogen receptor modulators (SERMs: tamoxifen and toremifene) as opposed to aromatase inhibitors (AIs: anastrozole, exemestane and letrozole)...
May 2, 2018: Heart: Official Journal of the British Cardiac Society
https://www.readbyqxmd.com/read/29719441/aromatase-inhibitors-in-premenopausal-women-with-breast-cancer-the-state-of-the-art-and-future-prospects
#8
REVIEW
M Pistelli, A Della Mora, Z Ballatore, R Berardi
Approximately 11% of patients with breast cancer (bca) are diagnosed before menopause, and because in most of those patients the tumour expresses a hormone receptor, treatment with endocrine interventions can be applied in any setting of disease (early or advanced). In the past, hormonal treatment consisted only of the estrogen receptor modulator tamoxifen, associated with luteinizing hormone-releasing hormone (lhrh); more recently, aromatase inhibitors (ais) have come into widespread use. The ais interfere with the last enzymatic step of estrogen synthesis in which androgens are converted into estrogens...
April 2018: Current Oncology
https://www.readbyqxmd.com/read/29719270/mechanisms-of-resistance-in-estrogen-receptor-positive-breast-cancer-overcoming-resistance-to-tamoxifen-aromatase-inhibitors
#9
REVIEW
Jamie N Mills, Alex C Rutkovsky, Antonio Giordano
Several mechanisms of resistance have been identified, underscoring the complex nature of estrogen receptor (ER) signaling and the many connections between this pathway and other essential signaling pathways in breast cancer cells. Many therapeutic targets of cell signaling and cell cycle pathways have met success with endocrine therapy and remain an ongoing area of investigation. This review focuses on two major pathways that have recently emerged as important opportunities for therapeutic intervention in endocrine resistant breast tumors: PI3K/AKT/mTOR cell signaling and cyclinD1/cyclin-dependent kinase 4/6 cell cycle pathways...
April 29, 2018: Current Opinion in Pharmacology
https://www.readbyqxmd.com/read/29704066/current-status-of-extended-adjuvant-endocrine-therapy-in-early-stage-breast-cancer
#10
REVIEW
Irene E G van Hellemond, Sandra M E Geurts, Vivianne C G Tjan-Heijnen
In the past decade, several endocrine treatment regimens have been developed for the adjuvant treatment of postmenopausal women with hormone receptor-positive early breast cancer, including tamoxifen, aromatase inhibitors (AI), or a combination of these. The standard duration of adjuvant endocrine treatment has been 5 years for a long time. Nevertheless, the high number of recurrences occurring after 5 years suggested that extended endocrine therapy could further improve outcome, which led to the start of several randomized clinical trials investigating the effects of extended use of endocrine therapy...
April 27, 2018: Current Treatment Options in Oncology
https://www.readbyqxmd.com/read/29688833/diabetes-after-hormone-therapy-in-breast-cancer-survivors-a-case-cohort-study
#11
Rola Hamood, Hatem Hamood, Ilya Merhasin, Lital Keinan-Boker
Purpose Breast cancer treatments have been associated with an increased risk of multiple health-related adverse outcomes, but the relationship with diabetes remains unclear. This study investigated the association between hormone therapy and diabetes risk in breast cancer survivors. Patients and Methods We performed a case-cohort study of 2,246 female survivors recruited from the Leumit health care fund who were diagnosed with primary nonmetastatic invasive breast cancer in 2002 through 2012. A 20% random subcohort was sampled at baseline, and all diabetes cases were identified...
April 24, 2018: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://www.readbyqxmd.com/read/29687661/clinicopathologic-features-of-hormone-receptor-positive-breast-cancer-patients-with-late-recurrence
#12
Takeshi Murata, Hiromitsu Jinno, Maiko Takahashi, Masayuki Shimoda, Tetsu Hayashida, Kaori Kameyama, Yuko Kitagawa
The number of long-term breast cancer survivors with a risk of late recurrence is increasing. Hormone-receptor-positive patients have greater risks of late recurrence. Although several studies demonstrated that extended adjuvant endocrine therapy reduces the incidence of late recurrence, it remains unclear which hormone-receptor-positive patients have greater risks of late recurrence. Hormone-receptor-positive breast cancer patients were retrospectively selected from the prospective database of primary breast cancer patients treated at Keio University Hospital from January 1989 to December 2003...
April 23, 2018: Breast Journal
https://www.readbyqxmd.com/read/29681616/progress-in-preventive-therapy-for-cancer-a-reminiscence-and-personal-viewpoint
#13
REVIEW
Jack Cuzick
Prophylactic drug treatment with aspirin, statins and anti-hypertensive agents has had a major impact on the incidence of cardiovascular disease and is now well established. Progress in therapeutic cancer prevention has been much slower; only recently have effective agents been clearly established. Breast cancer has led the way and endocrine agents used to treat it-notably tamoxifen and the aromatase inhibitors-have now been shown to have a substantial preventive effect as well. However, these agents carry some toxicity and thus identifying high-risk women who are likely to benefit most is a key priority...
April 23, 2018: British Journal of Cancer
https://www.readbyqxmd.com/read/29651409/incidence-of-comorbidities-in-women-with-breast-cancer-treated-with-tamoxifen-or-an-aromatase-inhibitor-an-australian-population-based-cohort-study
#14
Huah Shin Ng, Bogda Koczwara, David Roder, Theo Niyonsenga, Agnes Vitry
Background: The development of comorbidities has become increasingly relevant with longer-term cancer survival. Objective: To assess the pattern of comorbidities among Australian women with breast cancer treated with tamoxifen or an aromatase inhibitor. Design: Retrospective cohort study using Pharmaceutical Benefits Scheme (PBS) data (10% sample) from January 2003 to December 2014. Dispensing claims data were used to identify comorbidities and classified with the Rx-Risk-V model...
2018: Journal of Comorbidity
https://www.readbyqxmd.com/read/29644007/impact-of-adjuvant-hormonotherapy-on-radiation-induced-breast-fibrosis-according-to-the-individual-radiosensitivity-results-of-a-multicenter-prospective-french-trial
#15
Céline Bourgier, Florence Castan, Olivier Riou, Tan-Dat Nguyen, Karine Peignaux, Claire Lemanski, Jean-Léon Lagrange, Youlia Kirova, Eric Lartigau, Yazid Belkacemi, Sofia Rivera, Georges Noël, Sébastien Clippe, Françoise Mornex, Christophe Hennequin, Sophie Gourgou, Muriel Brengues, Pascal Fenoglietto, Esat Mahmut Ozsahin, David Azria
Background: To evaluate risk of severe breast fibrosis occurrence in patients treated by breast-conserving surgery, adjuvant radiotherapy and hormonotherapy (HT) according to individual radiosensitivity (RILA assay). Results: HT- and RILAhigh were the two independent factors associated with improved breast-fibrosis free survival (BFFS). BFFS rate at 36 months was lower in patients with RILAlow and HT+ than in patients with RILAhigh and HT- (75.8% and 100%, respectively; p = 0...
March 20, 2018: Oncotarget
https://www.readbyqxmd.com/read/29627127/the-action-of-estrogens-and-progestogens-in-the-young-female-breast
#16
Irene Zolfaroli, Juan J Tarín, Antonio Cano
Evidence from different sources sustains a pro-oncogenic role of hormones, estrogens and progestogens, on the breast. The issue is of interest for young women, who are exposed to the hormonal changes imposed by the ovarian cycle and, often, take hormones with contraceptive purposes. Experimental and clinical studies show that both estrogens and progesterone are involved in mammary development during puberty and lactation, the changes being observed across mammalian species, including humans. Estrogen receptors, and more particularly the alpha isoform, participate in molecular processes of stem cells differentiation and epithelial proliferation through paracrine actions implicating growth factors...
March 28, 2018: European Journal of Obstetrics, Gynecology, and Reproductive Biology
https://www.readbyqxmd.com/read/29619093/aromatase-inhibitors-are-associated-with-a-higher-fracture-risk-than-tamoxifen-a-systematic-review-and-meta-analysis
#17
REVIEW
Olivia L Tseng, John J Spinelli, Carolyn C Gotay, Wan Y Ho, Mary L McBride, Martin G Dawes
Background: In this paper, our aim was to systematically evaluate published evidence of bone fracture risk associated with tamoxifen and aromatase inhibitors in women aged 65 and under, and diagnosed with nonmetastatic breast cancer. Methods: We comprehensively searched MEDLINE, EMBASE and CINAHL databases from January 1997 through May 2015, and reference lists of the selected articles to identify English-language randomized controlled trials and cohort studies of fracture risk...
April 2018: Therapeutic Advances in Musculoskeletal Disease
https://www.readbyqxmd.com/read/29610032/personalized-prevention-in-high-risk-individuals-managing-hormones-and-beyond
#18
D Gareth Evans, Sacha J Howell, Anthony Howell
Increasing numbers of women are being identified at 'high-risk' of breast cancer, defined by The National Institute of Health and Care Excellence (NICE) as a 10-year risk of ≥8%. Classically women have been so identified through family history based risk algorithms or genetic testing of high-risk genes. Recent research has shown that assessment of mammographic density and single nucleotide polymorphisms (SNPs), when combined with established risk factors, trebles the number of women reaching the high risk threshold...
March 30, 2018: Breast: Official Journal of the European Society of Mastology
https://www.readbyqxmd.com/read/29607425/investigation-of-genotoxicity-risk-and-dna-repair-capacity-in-breast-cancer-patients-using-anastrozole
#19
Tugce Yesil Devecioglu, Fatih Aydogan, Gulden Zehra Omurtag, Nuran Senel Bese, Semra Sardas
OBJECTIVE: Breast cancer is the most common cancer in women worldwide and the incidence increases in postmenopausal women. Anastrozole is a non-steroidal (type II), third-generation aromatase inhibitor (AI) that is used in the treatment of postmenopausal estrogen-related breast cancer. Several studies have been conducted to assess the efficacy, safety, and superiority of AIs to tamoxifen; however, a literature search did not reveal a study that investigated the genotoxic potential of AIs...
2018: Northern Clinics of Istanbul
https://www.readbyqxmd.com/read/29578459/the-relationship-between-serum-e2-levels-and-recurrence-in-premenopausal-er-positive-breast-cancer-patients-a-retrospective-study
#20
Haruko Takuwa, Shigehira Saji, Masahiro Takada, Sachiko Takahara, Akira Yamauchi
BACKGROUND: Among estrogens, estradiol (E2) has the strongest physiological activity as a stimulator in estrogen receptor (ER)-positive breast cancer. The aim of this study is to investigate E2 dynamics during endocrine therapy and to explore the optimal environment in which tamoxifen (TAM) exhibits better efficacy for ER-positive premenopausal early breast cancer patients. METHODS: This is a retrospective study enrolled 194 patients with premenopausal ER-positive early-stage breast cancer who aging ≤45 years at onset and receiving luteinizing hormone-releasing hormone-agonist (LHRH-a) and TAM-therapy...
March 19, 2018: Breast Disease
keyword
keyword
30009
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"